Premium
Response to long‐term growth hormone therapy in patients affected by RASopathies and growth hormone deficiency: Patterns of growth, puberty and final height data
Author(s) -
Tamburrino Federica,
Gibertoni Dino,
Rossi Cesare,
Scarano Emanuela,
Perri Annamaria,
Montanari Francesca,
Fantini Maria Pia,
Pession Andrea,
Tartaglia Marco,
Mazzanti Laura
Publication year - 2015
Publication title -
american journal of medical genetics part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.064
H-Index - 112
eISSN - 1552-4833
pISSN - 1552-4825
DOI - 10.1002/ajmg.a.37260
Subject(s) - medicine , endocrinology , bone age , acromegaly , growth hormone deficiency , basal (medicine) , noonan syndrome , growth hormone , hormone , insulin
RASopathies are developmental disorders caused by heterozygous germline mutations in genes encoding proteins in the RAS‐MAPK signaling pathway. Reduced growth is a common feature. Several studies generated data on growth, final height (FH), and height velocity (HV) after growth hormone (GH) treatment in patients with these disorders, particularly in Noonan syndrome, the most common RASopathy. These studies, however, refer to heterogeneous cohorts in terms of molecular information, GH status, age at start and length of therapy, and GH dosage. This work reports growth data in 88 patients affected by RASopathies with molecularly confirmed diagnosis, together with statistics on body proportions, pubertal pattern, and FH in 33, including 16 treated with GH therapy for proven GH deficiency. Thirty‐three patients showed GH deficiency after pharmacological tests, and were GH‐treated for an average period of 6.8 ± 4.8 years. Before starting therapy, HV was −2.6 ± 1.3 SDS, and mean basal IGF1 levels were −2.0 ± 1.1 SDS. Long‐term GH therapy, starting early during childhood, resulted in a positive height response compared with untreated patients (1.3 SDS in terms of height‐gain), normalizing FH for Ranke standards but not for general population and Target Height. Pubertal timing negatively affected pubertal growth spurt and FH, with IGF1 standardized score increased from −2.43 to −0.27 SDS. During GH treatment, no significant change in bone age velocity, body proportions, or cardiovascular function was observed. © 2015 Wiley Periodicals, Inc.